Teva Pharmaceutical Industries Limited
36.85USD
+0.0900 (+0.24%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 14.9B | 15.8B | 16.5B | 17.3B | 16.6B | 17.3B |
| Q1 | 3.7B | 3.7B | 3.8B | 3.9B | 4.0B | — |
| Q2 | 3.8B | 3.9B | 4.2B | 4.2B | 4.1B | — |
| Q3 | 3.6B | 3.9B | 4.3B | 4.5B | 4.2B | — |
| Q4 | 3.9B | 4.5B* | 4.2B* | 1.5B | 4.2B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.20 | -.500 | -1.45 | 1.21 | 2.14 | 3.07 |
| Q1 | -.860 | -.200 | -.120 | .180 | .310 | — |
| Q2 | -.230 | -.780 | -.750 | .240 | -.490 | — |
| Q3 | .050 | .060 | -.390 | .370 | .699 | — |
| Q4 | -1.17 |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .414* |
| -.192* |
| .410 |
| .741 |
| — |